Shots: The collaboration is for development and commercialization of novel NK cell engager-based immunotherapeutics to treat multiple cancers Affimed’s will use its ROCK platform (Redirected Optimized Cell Killing) to develop NK cell and T cell-engaging Abs and Genentech will take care of all global clinical development and commercialization Affimed to receive an upfront $96M and […]Read More
Tags : Novel NK cells
Latest Posts
Categories
Related Topics
AbbVie
Acquire
Adults
Agreement
Amgen
approval
AstraZeneca
Bayer
Biosimilar
BMS
Collaborate
Collaborates
Collaboration
Commercialize
COVID-19
Develop
Development
Eli Lilly
EU
Exclusive
FDA
Gilead
GSK
Janssen
Launches
License
License Agreement
Merck
Novartis
P-III
patients
Pfizer
receives
Report
reports
results
Roche
Sanofi
Signs
study
Takeda
the US FDA
Treat
Treatment
US